Evidence map›Paper›PMID 32547151›Full record

ReviewClinical and experimental gastroenterology2020

Toxic Megacolon: Background, Pathophysiology, Management Challenges and Solutions.

Jiten Desai, Mohamed Elnaggar, Ahmed A Hanfy, Rajkumar Doshi

Erratum issuedOpen access · goldAbstract readReview
In one paragraph

Review in Clinical and experimental gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 59 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Therapeutics involved in managing initial and recurrentWorld journal of gastrointestinal pharmacology and therapeutics · 2024
    Review
  13. Review
  14. Article
  15. Article
  16. [Emergency diagnoses in the gastrointestinal tract].Radiologie (Heidelberg, Germany) · 2024
    Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Jiten DesaiDepartment of Internal Medicine, Nassau University of Medical Center, East Meadow, NY, USA.
Mohamed ElnaggarDepartment of Internal Medicine, University of Nevada Reno School of Medicine, Reno, NV, USA.ORCID 0000-0003-4415-2789
Ahmed A HanfyDepartment of Internal Medicine, University of Nevada Reno School of Medicine, Reno, NV, USA.
Rajkumar DoshiDepartment of Internal Medicine, University of Nevada Reno School of Medicine, Reno, NV, USA.ORCID 0000-0002-5618-2750
University of Nevada, Reno · USNassau University Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Toxic megacolon (TM) is one of the fatal complications of inflammatory bowel disease (IBD) or any infectious etiology of the colon that is characterized by total or partial nonobstructive colonic dilatation and systemic toxicity. It is associated with high morbidity and mortality, and surgical management is necessary for the majority of the cases. An accurate history and physical examination, plain radiographs of the abdomen, sigmoidoscopy, and, most important of all, awareness of the condition facilitate diagnosis in most cases. Operative intervention is warranted when massive hemorrhage, perforation, or peritonitis complicate the clinical scenario or medical therapy fails to control the disease. We sought to review the management challenges of TM and its possible management strategies in this article.

Indexed as

Clostridium difficile colitisinflammatory bowel diseasemanagement challenges and solutions for toxic megacolonnitric oxide synthasetoxic megacolon

Identifiers

PMID32547151
PMCPMC7245441
OpenAlexW3024913392

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.